Skip to main content
NewslettersWatchlist

Forte Biosciences Inc(FBRX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.6300
Day High0.6798
Open:0.6700
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Business Wire
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
Business Wire
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting
Business Wire
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update
Business Wire
Mr. David Gryska Appointed to Forte Biosciences Board of Directors
Business Wire
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
Business Wire
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors
Business Wire
Camac Partners Condemns Forte Biosciences’ Seemingly Defensive and Unjustifiable Capital Raise
Business Wire
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update
Business Wire
Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President
Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Business Wire
Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update
Globe NewsWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. – FBRX
Business Wire
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm
Business Wire
Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
Business Wire
Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7
Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Business Wire
Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update
Business Wire
Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update
Business Wire
Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update
Business Wire
Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update
Business Wire
Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th
Business Wire
Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st
Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Business Wire
Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd
Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
Business Wire
Forte Biosciences, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th
Business Wire
Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update
Business Wire
Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9
Business Wire
Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Profile

Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.